Medicus Pharma Advances SkinJect® into Registrational Trials for Gorlin Syndrome
Event summary
- Medicus Pharma submitted Protocol SKNJCT-005 to the FDA for SkinJect® registrational development in Gorlin Syndrome.
- The Phase 2b study will evaluate SkinJect® 200 mcg in up to 50 patients with Gorlin Syndrome and multiple basal cell carcinomas.
- Medicus aims for Orphan Drug Designation and Rare Pediatric Disease Priority Review Voucher by Q2 2026.
- SkinJect® demonstrated 64% clinical clearance in prior Phase 2 studies for nodular basal cell carcinoma.
The big picture
Medicus Pharma is targeting a high-unmet-need orphan indication with SkinJect®, potentially becoming the first FDA-approved lesion-directed therapy for Gorlin Syndrome. The strategic move aligns with broader trends in precision medicine and rare disease therapeutics, where targeted treatments can command premium pricing and market exclusivity. The Gorlin Syndrome program could serve as a commercial entry point for SkinJect® expansion into larger non-melanoma skin cancer markets.
What we're watching
- Regulatory Strategy
- Whether Medicus can secure Orphan Drug Designation and Rare Pediatric Disease Priority Review Voucher to accelerate SkinJect® approval.
- Clinical Efficacy
- The pace at which SkinJect® demonstrates clinically meaningful visual clearance in Gorlin Syndrome patients.
- Market Expansion
- How successful Gorlin Syndrome development could position SkinJect® for broader non-melanoma skin cancer indications.
Related topics